FIRST SCHEDULE
Regulations 2 and 13
First column
 
Second column
 
Third column
First Schedule treatment
 
Operative date for treatment or services received
 
Maximum amount that may be withdrawn
1.Radiotherapy treatment
 
 
 
 
(a)External radiotherapy (except hemi-body radiotherapy)
 
For course of treatment beginning before 1 June 1997
 
$60 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
For course of treatment beginning on or after 1 June 1997
 
$80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(b)Brachy-therapy with external radiotherapy
 
For course of treatment beginning before 1 June 1997
 
$150 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
For course of treatment beginning on or after 1 June 1997 but before 1 March 2021
 
$300 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
For course of treatment beginning on or after 1 March 2021
 
$360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(c)Brachy-therapy without external radiotherapy
 
For course of treatment beginning before 1 June 1997
 
$300 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
For course of treatment beginning on or after 1 June 1997
 
$360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(d)Superficial X-ray
 
For course of treatment beginning on or after 1 July 1990 but before 1 March 2021
 
$30 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(e)Stereotactic radiotherapy for cancer
 
For course of treatment beginning on or after 1 November 1999
 
$2,800 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(f)Hemi-body radiotherapy
 
For course of treatment beginning on or after 1 March 2021
 
$80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(g)Proton beam therapy for a Category 1 clinical indication listed in the Approved Indications for PBT
 
For course of treatment beginning on or after 1 October 2022
 
$80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(h)Proton beam therapy for a Category 2 clinical indication listed in the Approved Indications for PBT
 
For course of treatment beginning on or after 1 October 2022
 
$360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
(i)Proton beam therapy for a Category 3 clinical indication listed in the Approved Indications for PBT
 
For course of treatment beginning on or after 1 October 2022
 
$2,800 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
2.[Deleted by S 523/2009 wef 01/11/2009]
3.Treatment of neoplasms by chemotherapy
 
With effect from 1 November 2015 but before 1 September 2022
 
$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
4.Anti-retroviral drugs registered in Singapore for the medical treatment of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
 
With effect from 1st June 2001
 
$550 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
5.[Deleted by S 770/2022 wef 01/10/2022]
 
 
 
 
6.Blood transfusions and desferrioxamine for the medical treatment of thalassaemia
 
With effect from 1 June 1999 but before 1 November 2020
 
$350 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
With effect from 1 November 2020
 
$550 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
7.Hyperbaric oxygen therapy
 
With effect from 1st March 2002
 
$100 per treatment or the total credit balance in the member’s medisave account, whichever is the lower.
8.Intravenous antibiotic infusion at approved hospitals as designated by the Minister of Health
 
1 October 2002 to 30 June 2017 (both dates inclusive)
 
$600 per weekly cycle subject to a maximum claim of $2,400 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.
9.Rental of devices for long term oxygen therapy and infant continuous positive airway pressure therapy
 
With effect from 1 October 2002 but before 1 November 2020
 
$75 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
 
 
With effect from 1 November 2020
 
$150 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
10.Immunosuppressants for organ transplant
 
With effect from 1st January 2006
 
$300 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
11.Cancer scan or diagnostic test
 
With effect from 1 April 2008 but before 1 September 2022
 
$600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.
12.Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test
 
With effect from 1 September 2022 but before 1 December 2023
 
$600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.
12A.Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test for any neoplasm during a calendar year —
 
 
 
 
(a)where any cancer drug treatment is in respect of multiple neoplasms concurrently
 
With effect from 1 December 2023
 
$1,200 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.
(b)in any other case
 
With effect from 1 December 2023
 
$600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.
13.Approved cancer drug administered for the treatment of neoplasms:
 
 
 
 
(a)where only approved cancer drugs listed in the first tier of the CDL are administered in a month
 
With effect from 1 September 2022 but before 1 December 2023
 
$600 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
(b)where only approved cancer drugs listed in the second tier of the CDL are administered in a month
 
With effect from 1 September 2022 but before 1 December 2023
 
$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
(c)where approved cancer drugs listed in both the first tier and the second tier of the CDL are administered in a month
 
With effect from 1 September 2022 but before 1 December 2023
 
$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
14.Approved cancer drug administered for the treatment of —
 
 
 
 
(a)multiple neoplasms concurrently during a calendar month —
 
 
 
 
(i)in respect of each neoplasm treated with only approved cancer drugs listed in the first tier of the CDL
 
With effect from 1 December 2023
 
$600 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.
(ii)in respect of each neoplasm treated with only approved cancer drugs listed in the second tier of the CDL
 
With effect from 1 December 2023
 
$1,200 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.
(iii)in respect of each neoplasm treated with approved cancer drugs listed in both the first tier and the second tier of the CDL
 
With effect from 1 December 2023
 
$1,200 per month per patient in respect of each neoplasm, or the total credit balance in the member’s medisave account, whichever is the lower.
(b)only one neoplasm at a time, and paragraph (a) does not apply to the patient during that calendar month —
 
 
 
 
(i)where only approved cancer drugs listed in the first tier of the CDL are administered during that calendar month
 
With effect from 1 December 2023
 
$600 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
(ii)where only approved cancer drugs listed in the second tier of the CDL are administered during that calendar month
 
With effect from 1 December 2023
 
$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
(iii)where approved cancer drugs listed in both the first tier and the second tier of the CDL are administered in that calendar month
 
With effect from 1 December 2023
 
$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.
[S 773/2023 wef 01/12/2023]
[S 770/2022 wef 01/10/2022]
[S 716/2022 wef 01/09/2022]
[S 131/2021 wef 01/03/2021]
[S 899/2020 wef 01/11/2020]
[S 340/2017 wef 01/07/2017]
[S 625/2015 wef 01/11/2015]
[S 149/2008 wef 01/04/2008]
[S 731/2007 wef 01/01/2008]
[S 523/2009 wef 01/11/2009]
[S 548/2010 wef 01/10/2010]